Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1/2 4Phase 3 2Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1754Urinary Bladder Neoplasms 351Carcinoma, Renal Cell 217Breast Neoplasms 210Neoplasms 164Kidney Neoplasms 158Lung Neoplasms 101Colorectal Neoplasms 95Motor Activity 85Testicular Neoplasms 60Ovarian Neoplasms 53Colonic Neoplasms 48Melanoma 47Pancreatic Neoplasms 44Neoplasm Metastasis 43Non-Muscle Invasive Bladder Neoplasms 42Urinary Incontinence 40Head and Neck Neoplasms 40Carcinoma, Transitional Cell 40Uterine Cervical Neoplasms 39Disease 39Sarcoma 37Urologic Neoplasms 36Recurrence 35Anxiety Disorders 32Stomach Neoplasms 29Carcinoma, Non-Small-Cell Lung 29Lymphoma 28Endometrial Neoplasms 28Prostatic Hyperplasia 27

Interventions

Prednisone 1PE regimen 1Injections 1Etoposide 1Docetaxel 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Hormone Refractory Prostate Cancer × Genitourinary × Clear all
NCT02208583 2014-08-05

Molecular Phenotype Changes and Personalized Treatment for CRPC

Tianjin Medical University Cancer Institute and Hospital

Phase NA Unknown
150 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡